Mandy Jackson, US editor of Citeline’s Scrip, has published the below interview with Ali Pashazadeh, Treehill Partners CEO, discussing perspectives with various KOLs that M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.
Ali Pashazadeh comments that mid- to late development stage companies Treehill works with “ask us to give them a view of whether they’re transactable, whether they can raise money, whether they could be licensed or be acquired. We give them a very honest view of the likelihood of a transaction. And then the other thing we do is to say, if you want to improve the chance of a deal, what is the improvement in your clinical development strategy that could get you there.”
Read the full interview on Scrip (subscription required):